Baxter International, Inc.
One Baxter Parkway
Deerfield
Illinois
60015
United States
Tel: 847-948-2000
Fax: 847-948-3642
Website: http://www.baxter.com/
About Baxter International, Inc.
Baxter touches millions of lives every day. Our products and services are essential building blocks of healthcare.
You’ll find Baxter’s products and therapies on nearly every floor, in every department, in almost every hospital worldwide. You’ll find us in clinics and in the home. Patients and providers rely on Baxter for lifesaving renal and medical products, including intravenous (IV) solutions, systems and administrative sets, IV infusion parenteral nutrition, perioperative care, pharmacy devices and software, acute renal care, and home and in-center dialysis.
Our mission to save and sustain lives inspires our work and our commitment to expanding access to care, providing cost-effective healthcare solutions, delivering quality products and advancing innovations for the world.
Our commitment to our mission means we are there when patients and healthcare professionals need us, during the critical moments that matter most.
YEAR FOUNDED:
1931
LEADERSHIP:
CEO: José (Joe) E. Almeida
CMO: James R. Gavin III
CTO: Uma Chowdhry
CFO: Peter Hellman
PRODUCTS:
All Products
FOLLOW BAXTER INTERNATIONAL:
Tweets by Baxer International
931 articles with Baxter International, Inc.
-
Baxter International Inc. to Host Webcast of Annual Meeting of Stockholders
4/2/2018
Baxter International, Inc. will host a webcast of its Annual Meeting of Stockholders on Tuesday, May 8, 2018 at 9:00 a.m. Central Time.
-
Shire stock prices jumped up to 26 percent on rumors that Takeda Pharmaceuticals was considering a buyout.
-
Baxter Completes Acquisition of RECOTHROM and PREVELEAK to Broaden Surgical Hemostat and Sealant Portfolio
3/19/2018
RECOTHROM Thrombin topical (Recombinant) is the first and only stand-alone recombinant thrombin and PREVELEAK Surgical Sealant is used in vascular reconstruction.
-
Baxter Declares Quarterly Dividend and Announces Expanded Share Repurchase Authorization
2/20/2018
Baxter International Inc. (NYSE:BAX) today announced a quarterly cash dividend and an expanded authorization for its share repurchase program.
-
Baxter to Present at the Raymond James & Associates 39th Annual Institutional Investors Conference
2/7/2018
Baxter will present at the Raymond James & Associates 39th Annual Institutional Investors Conference on Tuesday, March 6, 2018, in Orlando, Fla. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 4:35 p.m. EST.
-
Baxter Reports 2017 Fourth-Quarter and Full-Year Results
2/1/2018
Baxter International, Inc. today reported results for the fourth quarter and full-year ended December 31, 2017, and provided its financial guidance for 2018.
-
Baxter Announces U.S. FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
1/22/2018
Baxter announced the U.S. Food and Drug Administration (FDA) approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin).
-
Puma Hits a Huge Roadblock
1/17/2018
Despite some safety concerns such as severe diarrhea, the FDA approved Puma's breast cancer drug Nerlynx in July 2017. -
Baxter Launches Arisure Closed System Transfer Device to Help Prevent Hazardous Drug Exposure and Maintain Medication Sterility
1/11/2018
Baxter today announced a distribution agreement for the U.S. launch of the Arisure Closed System Transfer device.
-
Baxter to Host Fourth Quarter 2017 Financial Results Conference Call for Investors
1/10/2018
Baxter will host a conference call to discuss its fourth quarter 2017 financial results on Thursday, February 1, 2018, at 7:30 a.m. Central Standard Time.
-
Baxter Announces Agreement to Broaden Portfolio of Innovative Surgical Products
1/8/2018
Baxter announced an agreement to acquire two hemostat and sealant products from Mallinckrodt plc: RECOTHROM Thrombin topical (Recombinant), the first and only stand-alone recombinant thrombin, and PREVELEAK Surgical Sealant, which is used in vascular reconstruction.
-
Baxter Declares Quarterly Dividend
11/14/2017
The dividend is payable on January 2, 2018, to stockholders of record as of December 1, 2017. The indicated annual dividend rate is $0.64 per share.
-
Baxter Presents Data on the Role of SHARESOURCE Telehealth Platform in Helping the Clinical Management of Peritoneal Dialysis Patients
11/7/2017
Presented at the American Society of Nephrology’s annual Kidney Week Congress, Oct. 31- Nov. 5, the exploratory studies show how SHARESOURCE data may provide an early indicator of impending peritonitis, or evidence of PD catheter dysfunction.
-
Baxter Highlights New Clinical Data Showing HDx Enabled by THERANOVA Removes Mid-Sized Uremic Toxins During Dialysis
11/6/2017
The studies were conducted by clinicians in the United Kingdom and Germany, and were presented at the American Society of Nephrology’s annual Kidney Week Congress, Oct. 31-Nov. 5.
-
Baxter Supports 27 Abstract Presentations at ASN Kidney Week to Advance Scientific Exchange Focused on New Standards of Renal Care
11/3/2017
Baxter today announced the presentation of 27 abstracts at the American Association of Nephrology (ASN) Kidney Week, Oct. 31 - Nov. 5, to support greater scientific exchange across the continuum of renal care.
-
Baxter Launches PD-First Program for Employees and Families
11/1/2017
Baxter announced a new PD-first program for its employees and family members aimed at improving education and awareness of dialysis treatment options, including peritoneal dialysis (PD).
-
Baxter Reports Third-Quarter 2017 Results and Updates Financial Outlook for Full-Year 2017
10/25/2017
Baxter International Inc. today reported results for the third quarter of 2017 and updated its financial outlook for full-year 2017.
-
Baxter International Provides Update On Puerto Rico Recovery Status Post Hurricane Maria
10/13/2017
-
Baxter International Expects Hit on Q4 Revenue Due to Hurricane Maria
10/13/2017
-
Baxter International To Host Third Quarter 2017 Financial Results Conference Call For Investors
9/29/2017